NBIX(Neurocrine Biosciences, Inc.) · 财务报表

NBIX(Neurocrine Biosciences, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$1.13B$1.49B$1.89B$2.36B$2.86B
毛利润$1.12B$1.47B$1.85B$2.32B$2.81B
营业利润$102.50M$249.00M$250.90M$570.50M$619.10M
净利润$89.60M$154.50M$249.70M$341.30M$478.60M
经营现金流$256.50M$339.40M$389.90M$595.40M$782.70M
自由现金流$233.10M$322.90M$361.60M$557.20M$748.70M
摊薄每股收益$0.92$1.56$2.47$3.29$4.67

Neurocrine Biosciences, Inc. NBIX